Lexicon Pharmaceuticals Inc
LXRX1.250USD
-0.180-12.59%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
457.23MMarket Cap
LossP/E TTM
More Details of Lexicon Pharmaceuticals Inc Company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Lexicon Pharmaceuticals Inc Info
Ticker SymbolLXRX
Company nameLexicon Pharmaceuticals Inc
IPO dateApr 07, 2000
CEOMr. Michael Exton
Number of employees103
Security typeOrdinary Share
Fiscal year-endApr 07
Address2445 Technology Forest Blvd
CityTHE WOODLANDS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77381
Phone12818633000
Websitehttps://www.lexpharma.com/
Ticker SymbolLXRX
IPO dateApr 07, 2000
CEOMr. Michael Exton
Company Executives of Lexicon Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Dr. Judith L. Swain, M.D.
Dr. Judith L. Swain, M.D.
Independent Director
Independent Director
85.17K
+76.11%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Independent Director
Independent Director
36.81K
--
Ms. Wendy E. Mcdermott
Ms. Wendy E. Mcdermott
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
Ms. Kristen L. Alexander
Ms. Kristen L. Alexander
Vice President - Finance and Accounting
Vice President - Finance and Accounting
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Raymond (Ray) Debbane
Mr. Raymond (Ray) Debbane
Independent Chairman of the Board
Independent Chairman of the Board
1.39M
+2.73%
Dr. Alan J. Main, Ph.D.
Dr. Alan J. Main, Ph.D.
Executive Vice President - Innovation and Chemical Sciences
Executive Vice President - Innovation and Chemical Sciences
339.10K
--
Mr. Philippe J. Amouyal
Mr. Philippe J. Amouyal
Independent Director
Independent Director
285.17K
+14.82%
Mr. Brian T. Crum
Mr. Brian T. Crum
Senior Vice President, General Counsel
Senior Vice President, General Counsel
260.81K
--
Mr. Christopher J. (Chris) Sobecki
Mr. Christopher J. (Chris) Sobecki
Independent Director
Independent Director
203.87K
+22.03%
Dr. Samuel L. (Sam) Barker, Ph.D.
Dr. Samuel L. (Sam) Barker, Ph.D.
Independent Director
Independent Director
124.46K
+42.00%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Artal International S.C.A.
37.47%
Invus Public Equities Advisors, LLC
10.71%
Fidelity Management & Research Company LLC
10.49%
The Vanguard Group, Inc.
2.62%
Ulys, L.L.C.
1.50%
Other
37.20%
Shareholders
Shareholders
Proportion
Artal International S.C.A.
37.47%
Invus Public Equities Advisors, LLC
10.71%
Fidelity Management & Research Company LLC
10.49%
The Vanguard Group, Inc.
2.62%
Ulys, L.L.C.
1.50%
Other
37.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
65.31%
Hedge Fund
3.63%
Investment Advisor/Hedge Fund
2.33%
Individual Investor
1.23%
Research Firm
0.53%
Family Office
0.06%
Bank and Trust
0.02%
Venture Capital
0.02%
Other
26.87%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
304
260.48M
71.73%
-53.78M
2025Q2
320
279.54M
76.92%
-43.06M
2025Q1
325
276.43M
76.32%
-62.57M
2024Q4
309
308.33M
85.37%
-6.09M
2024Q3
300
300.67M
83.18%
-4.62M
2024Q2
291
290.96M
80.51%
+37.02M
2024Q1
279
184.47M
74.41%
-20.75M
2023Q4
274
194.11M
79.36%
-11.88M
2023Q3
271
200.84M
82.07%
-4.66M
2023Q2
276
200.76M
82.17%
+43.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Artal International S.C.A.
136.18M
37.47%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
38.92M
10.71%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
38.14M
10.49%
+3.59M
+10.41%
Jun 30, 2025
The Vanguard Group, Inc.
8.85M
2.44%
-706.14K
-7.39%
Jun 30, 2025
Ulys, L.L.C.
5.45M
1.5%
--
--
Dec 05, 2024
Schonfeld Strategic Advisors LLC
4.58M
1.26%
-3.64M
-44.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.17M
0.87%
-6.04M
-65.57%
Jun 30, 2025
Sessa Capital
3.00M
0.83%
+3.00M
--
Jun 30, 2025
CIBC Private Wealth Management
2.45M
0.67%
+210.40K
+9.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.38M
0.65%
-1.31M
-35.55%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.6%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Fidelity MSCI Health Care Index ETF
0%
Global X Russell 2000 ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
FlexShares Morningstar US Market Factor Tilt Index Fund
0%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.6%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Fidelity MSCI Health Care Index ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
SPDR Portfolio MSCI Global Stock Market ETF
Proportion0%
FlexShares Morningstar US Market Factor Tilt Index Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
